Mumbai: Global pharma major Lupin Limited has announced the launch of Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, ...
Dasatinib Tablets (RLD Sprycel®) had an estimated annual sale of USD 930 million in the U.S. (IQVIA MAT Oct 2025).
Pharmaceutical company Lupin has introduced Dasatinib Tablets, a generic cancer treatment medication, in the US market following approval from the USFDA.
Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80mg, 100 mg, and 140 mg are bioequivalent to Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated fo ...
Lupin launches generic Dasatinib tablets in the US after USFDA approval. A cancer treatment for leukemia, with estimated annual sales of USD 930 million.
Drug firm Lupin on Monday said it has launched a generic cancer treatment medication in the US. The company has launched Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results